Analyst Ratings for Seattle Genetics (sgen)
sgen Rating Summary
sgen Price Target Summary
- Highest: $37.00 (Goldman Sachs)
- Lowest: $10.00 (Citadel Securities)
- Average: $20.14
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$20.14 (-43.5%)
Avg. $ Target:
$20.14 (-43.5%)
| Date | Firm | Type | Rating (Past) |
PT (Past) |
Start $ | End $ | % Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/7/2013 | Goldman Sachs | New Coverage | Neutral (N/A) |
37.00 (N/A) |
36.33 | 35.64 | -1.9% | Details |
| 2/13/2013 | Needham & Company | Downgrade | Hold (Buy) |
N/A (N/A) |
29.24 | 35.64 | 21.89% | Details |
| 11/13/2012 | Credit Suisse | New Coverage | Outperform (N/A) |
28.00 (N/A) |
23.45 | 35.64 | 51.98% | Details |
| 11/9/2012 | Guggenheim | New Coverage | Neutral (N/A) |
24.00 (N/A) |
23.23 | 35.64 | 53.42% | Details |
| 11/8/2012 | Cantor Fitzgerald | Downgrade | Sell (Hold) |
20.00 (30.00) |
24.47 | 35.64 | 45.65% | Details |
| 9/7/2012 | Oppenheimer | Downgrade | Perform (Outperform) |
N/A (N/A) |
29.68 | 35.64 | 20.08% | Details |
| 7/5/2012 | ThinkEquity | New Coverage | Buy (N/A) |
30.00 (N/A) |
25.83 | 35.64 | 37.98% | Details |
| 7/2/2012 | Piper Jaffray | Downgrade | Underweight (Neutral) |
20.00 (N/A) |
25.39 | 35.64 | 40.37% | Details |
| 12/9/2011 | WJB Capital | New Coverage | Sell (N/A) |
11.00 (N/A) |
17.98 | 35.64 | 98.22% | Details |
| 10/5/2011 | Summer Street | New Coverage | Sell (N/A) |
12.00 (N/A) |
20.34 | 35.64 | 75.22% | Details |
| 9/16/2011 | Madison Williams | New Coverage | Sell (N/A) |
10.00 (N/A) |
18.72 | 35.64 | 90.38% | Details |
| 8/8/2011 | Citadel Securities | New Coverage | Reduce (N/A) |
10.00 (N/A) |
13.84 | 35.64 | 157.51% | Details |
| 7/11/2011 | Chardan Capital | Downgrade | Sell (N/A) |
N/A (N/A) |
21.08 | 35.64 | 69.07% | Details |
| 5/2/2011 | BofA/Merrill Lynch | New Coverage | Buy (N/A) |
N/A (N/A) |
16.45 | 35.64 | 116.66% | Details |
| 3/9/2011 | BioLogic Equity Research | New Coverage | Sell (N/A) |
N/A (N/A) |
14.93 | 35.64 | 138.71% | Details |
